Glut-1 Expression Correlates with Basal-like Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Glucose transporter 1 (Glut-1) is a key protein in glucose metabolism.
• Basal-like breast cancer (BLBC) is an aggressive subtype with poor prognosis and limited targeted therapies.
• Understanding Glut-1 expression in BLBC is crucial for identifying new treatment strategies.

Purpose of the Study:

• To investigate the immunohistochemical (IHC) expression of Glut-1 in BLBC.
• To compare Glut-1 expression between BLBC and non-BLBC subtypes.
• To explore the association of Glut-1 expression with clinicopathologic features in breast cancer.

Main Methods:

• Retrospective analysis of 523 invasive breast carcinoma cases.
• Immunohistochemical (IHC) staining for Glut-1, cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), and p53.
• Classification of BLBC based on estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2) negativity, and CK5/6 and/or EGFR positivity.

Main Results:

• Glut-1 was significantly overexpressed in BLBC (76.4%) compared to non-BLBC (23.8%) (P < .001).
• Glut-1 expression strongly correlated with high histologic grade, ER/PR negativity, CK5/6 positivity, EGFR expression, and high p53 expression (P < .001).
• No significant correlation was found between Glut-1 immunostaining and patient outcome.

Conclusions:

• Glut-1 is significantly associated with the basal-like breast cancer subtype.
• Glut-1 represents a potential therapeutic target for aggressive BLBC.
• Further research is warranted to explore Glut-1-targeted therapies for BLBC.